Hyperlipidaemia indicates high level of fats (or lipids) in the blood. Hyperlipidemia is one of the major culprits for various cardiovascular and central nervous system disorders. Both genetic disorders and diet enriched with saturated fats and cholesterol, contribute to the elevated lipid levels in indian population as well as in many other developed countries around the world. The present study was undertaken for hypolipidemic effects of atorvastatin with Emblica officinalis (amla) in patients having hypercholesteremia. A prospective randomized open label study was done. Out of 93 patients, 45 patients (Group–A) were given two tablet of Amla (500 mg) daily, while the other 48 patients (Group–B) received one tablet of Atorvastatin (10 mg) daily for 16 weeks. All routine biochemical investigations including lipid profile were performed before starting the intervention as well as after completion of each treatment round i.e. at the end of 4 weeks, 8 weeks, 12 weeks & 16 weeks. Amla showed significant increase in HDL and decrease in triglyceride level (P < 0.05) at the end of 16 wks while atorvastatin has shown better effect on TC, LDL and VLDL (P < 0.05). There was no adverse drug event in either group. In our study on amla when compared with atorvastatin, amla has been shown better effect on TG and HDL while atorvastatin has shown better effect on TC, LDL and VLDL.